keyword
https://read.qxmd.com/read/27015968/informing-hot-flash-treatment-decisions-for-breast-cancer-survivors-a-systematic-review-of-randomized-trials-comparing-active-interventions
#21
REVIEW
Claire Johns, Susan M Seav, Sally A Dominick, Jessica R Gorman, Hongying Li, Loki Natarajan, Jun James Mao, H Irene Su
Patient-centered decision making about hot flash treatments often incorporates a balance of efficacy and side effects in addition to patient preference. This systematic review examines randomized controlled trials (RCTs) comparing at least two non-hormonal hot flash treatments in breast cancer survivors. In July 2015, PubMed, SCOPUS, CINAHL, Cochrane, and Web of Science databases were searched for RCTs comparing active, non-hormonal hot flash treatments in female breast cancer survivors. Thirteen trials were included after identifying 906 potential studies...
April 2016: Breast Cancer Research and Treatment
https://read.qxmd.com/read/26466611/endocrine-dilemma-managing-menopausal-symptoms-after-breast-cancer
#22
REVIEW
John Eden
Managing the symptoms of menopause after a diagnosis of breast cancer offers some unique clinical challenges. For some women, vasomotor symptoms can be severe and debilitating, and hormone therapy is at least relatively contraindicated. Non-oestrogen therapies for hot flushes include SSRIs, clonidine, gabapentin and perhaps black cohosh extracts. Vulvovaginal atrophy can usually be alleviated by simple moisturizers, although some may need specialized physiotherapy such as vaginal dilators. In a small number, topical oestrogens may be the only treatment that works...
March 2016: European Journal of Endocrinology
https://read.qxmd.com/read/26304905/electroacupuncture-versus-gabapentin-for-hot-flashes-among-breast-cancer-survivors-a-randomized-placebo-controlled-trial
#23
RANDOMIZED CONTROLLED TRIAL
Jun J Mao, Marjorie A Bowman, Sharon X Xie, Deborah Bruner, Angela DeMichele, John T Farrar
PURPOSE: Hot flashes are a common and debilitating symptom among survivors of breast cancer. This study aimed at evaluating the effects of electroacupuncture (EA) versus gabapentin (GP) for hot flashes among survivors of breast cancer, with a specific focus on the placebo and nocebo effects. PATIENTS AND METHODS: We conducted a randomized controlled trial involving 120 survivors of breast cancer experiencing bothersome hot flashes twice per day or greater. Participants were randomly assigned to receive 8 weeks of EA or GP once per day with validated placebo controls (sham acupuncture [SA] or placebo pills [PPs])...
November 1, 2015: Journal of Clinical Oncology
https://read.qxmd.com/read/26160608/a-crossover-study-comparing-gabapentin-and-fluoxetine-for-the-treatment-of-vasomotor-symptoms-among-postmenopausal-women
#24
RANDOMIZED CONTROLLED TRIAL
Mojgan Rahmanian, Arash Mohseni, Raheb Ghorbani
OBJECTIVE: To compare the effectiveness of fluoxetine and gabapentin for treatment of vasomotor symptoms (VMS) after the menopause. METHODS: Between March 2011 and March 2012, a randomized crossover study was performed at a center in Semnan, Iran, among postmenopausal women aged 45-57 years with hot flashes (≥2 per day for previous 4 months) for which they had received no previous treatment. Participants were divided into two groups with consecutive numbers assigned in order of recruitment...
October 2015: International Journal of Gynaecology and Obstetrics
https://read.qxmd.com/read/26002789/sleep-disturbances-in-menopausal-women-aetiology-and-practical-aspects
#25
REVIEW
Marie Bruyneel
Sleep deteriorates with age. The menopause is often a turning point for women's sleep, as complaints of insomnia increase significantly thereafter. Insomnia can occur as a secondary disorder to hot flashes, mood disorders, medical conditions, psychosocial factors, underlying intrinsic sleep disorders, such as obstructive sleep apnoea (OSA) or restless legs syndrome (RLS), or it can be a primary disorder. Since unrecognized OSA can have dramatic health-related consequences, menopausal women complaining of persisting sleep disturbances suggesting primary insomnia or intrinsic sleep disorders should be referred to a sleep specialist for a comprehensive sleep assessment...
July 2015: Maturitas
https://read.qxmd.com/read/25982505/emas-position-statement-non-hormonal-management-of-menopausal-vasomotor-symptoms
#26
REVIEW
Gesthimani Mintziori, Irene Lambrinoudaki, Dimitrios G Goulis, Iuliana Ceausu, Herman Depypere, C Tamer Erel, Faustino R Pérez-López, Karin Schenck-Gustafsson, Tommaso Simoncini, Florence Tremollieres, Margaret Rees
AIM: To review non-hormonal therapy options for menopausal vasomotor symptoms. The current EMAS position paper aims to provide to provide guidance for managing peri- and postmenopausal women who cannot or do not wish to take menopausal hormone therapy (MHT). MATERIAL AND METHODS: Literature review and consensus of expert opinion. RESULTS: Non-hormonal management of menopausal symptoms includes lifestyle modifications, diet and food supplements, non-hormonal medications and application of behavioral and alternative medicine therapies...
July 2015: Maturitas
https://read.qxmd.com/read/25713759/a-systematic-review-of-non-hormonal-treatments-of-vasomotor-symptoms-in-climacteric-and-cancer-patients
#27
JOURNAL ARTICLE
Juergen Drewe, Kathleen A Bucher, Catherine Zahner
The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation...
2015: SpringerPlus
https://read.qxmd.com/read/25681847/hormonal-and-nonhormonal-treatment-of-vasomotor-symptoms
#28
REVIEW
Miriam S Krause, Steven T Nakajima
This article focuses on the cause, pathophysiology, differential diagnosis of, and treatment options for vasomotor symptoms. In addition, it summarizes important points for health care providers caring for perimenopausal and postmenopausal women with regard to health maintenance, osteoporosis, cardiovascular disease, and vaginal atrophy. Treatment options for hot flashes with variable effectiveness include systemic hormone therapy (estrogen/progestogen), nonhormonal pharmacologic therapies (selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, clonidine, gabapentin), and nonpharmacologic therapy options (behavioral changes, acupuncture)...
March 2015: Obstetrics and Gynecology Clinics of North America
https://read.qxmd.com/read/25591030/treating-recurrent-postmenopausal-vasomotor-symptoms-in-a-patient-with-a-positive-family-history-for-breast-cancer
#29
JOURNAL ARTICLE
Christine Leong, Jennifer Lake
OBJECTIVE: To report a case of recurrent hot flashes unresponsive to gabapentin in a postmenopausal patient with a positive family history of breast cancer. CASE SUMMARY: A 69-year-old Caucasian female experienced a recurrence of debilitating hot flashes for the past eight months. More recently, she failed a two-month trial of gabapentin 600 mg by mouth at bedtime after she previously received effective hormone replacement therapy (HRT) seven years ago with near-complete resolution of her symptoms...
January 2015: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://read.qxmd.com/read/25427609/hot-flash-management-update-of-the-evidence-for-patients-with-cancer
#30
REVIEW
Marcelle Kaplan, Suzanne Mahon
Hot flashes are a distressing symptom frequently experienced by survivors of breast cancer or prostate cancer who are receiving estrogen or androgen-deprivation therapies. The frequency and intensity of hot flashes can lead to diminished quality of life and decreased adherence with prescribed antineoplastic therapies. This evidence-based review synthesizes and updates the findings of the highest quality evidence-based studies of interventions to manage hot flashes resulting from cancer therapies in patients with breast or prostate cancer since the initial Putting Evidence Into Practice review of hot flashes in 2011...
2014: Clinical Journal of Oncology Nursing
https://read.qxmd.com/read/25097095/adverse-effects-of-androgen-deprivation-therapy-and-strategies-to-mitigate-them
#31
REVIEW
Paul L Nguyen, Shabbir M H Alibhai, Shehzad Basaria, Anthony V D'Amico, Philip W Kantoff, Nancy L Keating, David F Penson, Derek J Rosario, Bertrand Tombal, Matthew R Smith
CONTEXT: Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive and advanced prostate cancer, but it has also been associated with adverse effects on bone, metabolic, cardiovascular, sexual, and cognitive health as well as body composition. OBJECTIVE: To review the current literature on the adverse effects of ADT and strategies for ameliorating harm from ADT. EVIDENCE ACQUISITION: The Medline database (through PubMed) was searched from inception to August 1, 2013, for studies documenting the side effects of ADT and for randomized and prospective trials of interventions to mitigate those side effects...
May 2015: European Urology
https://read.qxmd.com/read/25045284/androgen-deprivation-therapy-for-prostate-cancer-long-term-safety-and-patient-outcomes
#32
REVIEW
Hamed Ahmadi, Siamak Daneshmand
Androgen deprivation therapy (ADT) constitutes the first-line treatment for patients with locally advanced tumors, recurrent or metastatic disease. Given its widespread use, clinicians should be familiar with common side effects of this treatment. This review focuses on common side effects of ADT and available treatment options to control the side effects. Also, it briefly compares continuous ADT with other therapeutic approaches for androgen deprivation in prostate cancer patients. Similar to hormonal medications, newer non-hormonal therapeutic options including gabapentin and acupuncture have at best moderate effect in controlling hot flashes in patients on ADT...
2014: Patient related Outcome Measures
https://read.qxmd.com/read/24991606/comparison-of-gabapentin-with-estrogen-for-treatment-of-hot-flashes-in-post-menopausal-women
#33
JOURNAL ARTICLE
Zahra Allameh, Safoura Rouholamin, Sonia Valaie
OBJECTIVE: Various non-hormonal agents have been used for the treatment of hot flashes in women with menopause. Some studies have reported that gabapentin appears to be an effective and well-tolerated treatment modality. The aim of this study was to evaluate whether the treatment with gabapentin is effective in reducing hot flash frequency and severity and also to compare gabapentin 100 mg/day, 300 mg/day and conjugated estrogen in this regards. METHODS: In this comparative clinical trial, 100 post-menopausal women attending outpatient clinics of Isfahan University hospitals were included from April 2008 to February 2009...
April 2013: Journal of Research in Pharmacy Practice
https://read.qxmd.com/read/24171880/the-effect-of-gabapentin-on-intensity-and-duration-of-hot-flashes-in-postmenopausal-women-a-randomized-controlled-trial
#34
RANDOMIZED CONTROLLED TRIAL
Najmieh Saadati, Razieh Mohammadjafari, Solmaz Natanj, Parvin Abedi
BACKGROUND: Menopause is the stage of time in which the menstruation stops following the loss of ovarian activity. The purpose of this study was to find out the effectiveness of gabapentin on hot flashes in postmenopausal women. MATERIALS & METHODS: A randomized controlled trial from Feb 2010 to 2011 was conducted. Sixty postmenopausal women who were referred to obstetrics and gynecology ward of two educational hospitals were recruited and divided into two groups (intervention and control)...
November 2013: Global Journal of Health Science
https://read.qxmd.com/read/24149930/phase-3-randomized-controlled-study-of-gastroretentive-gabapentin-for-the-treatment-of-moderate-to-severe-hot-flashes-in-menopause
#35
RANDOMIZED CONTROLLED TRIAL
JoAnn V Pinkerton, Risa Kagan, David Portman, Rekha Sathyanarayana, Michael Sweeney
OBJECTIVE: The goal of this study was to evaluate the efficacy and safety of gastroretentive gabapentin (G-GR) for the treatment of moderate-to-severe menopausal hot flashes. METHODS: The primary endpoints of this randomized, placebo-controlled study of G-GR (600 mg am/1,200 mg pm) were the mean daily frequency and severity of hot flashes at weeks 4 and 12. Secondary endpoints included Patients' Global Impression of Change, Clinicians' Global Impression of Change, and daily sleep interference at week 24...
June 2014: Menopause: the Journal of the North American Menopause Society
https://read.qxmd.com/read/24022390/randomised-controlled-trial-comparing-hypnotherapy-versus-gabapentin-for-the-treatment-of-hot-flashes-in-breast-cancer-survivors-a-pilot-study
#36
JOURNAL ARTICLE
Shannon Maclaughlan David, Sandra Salzillo, Patrick Bowe, Sandra Scuncio, Bridget Malit, Christina Raker, Jennifer S Gass, C O Granai, Don S Dizon
OBJECTIVES: To compare the efficacy of hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors, and to evaluate the feasibility of conducting a clinical trial comparing a drug with a complementary or alternative method (CAM). DESIGN: Prospective randomised trial. SETTING: Breast health centre of a tertiary care centre. PARTICIPANTS: 15 women with a personal history of breast cancer or an increased risk of breast cancer who reported at least one daily hot flash...
September 10, 2013: BMJ Open
https://read.qxmd.com/read/23974271/the-efficacy-of-nonestrogenic-therapy-to-hot-flashes-in-cancer-patients-under-hormone-manipulation-therapy-a-systematic-review-and-meta-analysis
#37
REVIEW
N Yamaguchi, Y Okajima, T Fujii, A Natori, D Kobayashi
PURPOSE: The incidence of hot flashes under hormone manipulation therapy is so high that this symptom caused by sex hormone blocking agents has been bothering patients and has a negative impact on their quality of life. Venlafaxine and gabapentin are most promising novel nonestrogenic agents to control the symptom. We seek to quatitatively summarize the efficacy of these novel agents. PATIENTS AND METHODS: We conducted a meta-analysis of randomized controlled studies on the efficacy of venlafaxine/gabapentin to hot flashes in cancer patient under hormone deprivation therapies...
October 2013: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/23950657/potential-role-of-gabapentin-and-extended-release-gabapentin-in-the-management-of-menopausal-hot-flashes
#38
JOURNAL ARTICLE
Manisha Yadav, Judith Volkar
About 80% of postmenopausal women experience vasomotor symptoms, such as hot flashes and night sweats - symptoms that are associated with sleep disruption and can lead to fatigue and mood changes. Moreover, hot flashes can be embarrassing for women, causing difficulties at work and in their social lives. Many therapies have been advocated for relief of vasomotor symptoms, but only hormone therapy has been US Food and Drug Administration approved. However, after the Women's Health Initiative Study suggested that there was a correlation between hormone therapy and increased risk for breast cancer and cardiovascular events, many women stopped taking hormone therapy, and many do not want to initiate it...
2013: International Journal of General Medicine
https://read.qxmd.com/read/23435567/pharmacological-and-non-hormonal-treatment-of-hot-flashes-in-breast-cancer-survivors-cepo-review-and-recommendations
#39
REVIEW
Sylvain L'Espérance, Suzanne Frenette, Anne Dionne, Jean-Yves Dionne
PURPOSE: Breast cancer patients frequently report hot flashes. Given that conventional hormone replacement therapy is generally contraindicated for them, other therapeutic modalities must be considered. The purpose of this review was to develop evidence-based recommendations on non-hormonal pharmacological interventions, including natural health products, for managing hot flashes in women undergoing treatment for breast cancer or with a history of breast cancer. METHODS: A review of the scientific literature published between January 2000 and December 2011 was performed...
May 2013: Supportive Care in Cancer
https://read.qxmd.com/read/23351025/androgen-deprivation-therapy-evidence-based-management-of-side-effects
#40
REVIEW
Hamed Ahmadi, Siamak Daneshmand
UNLABELLED: WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The benefits of androgen deprivation therapy (ADT) are well recognized and a multitude of studies have documented the benefits of ADT in conjunction with other therapies. Given the widespread use of ADT due to its important clinical implications, it is imperative that clinicians understand the side effects to limit treatment-related morbidity. There are numerous well recognized adverse effects of ADT, including vasomotor flushing, loss of libido and impotence, fatigue, gynaecomastia, anaemia, osteoporosis and metabolic complications, as well as effects on cardiovascular health and bone density...
April 2013: BJU International
keyword
keyword
119079
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.